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A B S T R A C T
Bardet-Biedl syndrome (BBS) is an autosomal recessive ciliopathy with a wide range of symptoms including obesity, retinal dystrophy, polycystic kidney disease,
polydactyly, hypogonadism and learning diﬃculties. Here we describe the successful generation of an induced pluripotent stem cell (iPSC) KCi001-A from a BBS
patient compound heterozygous for two disease causing BBS1 variants c.1169T>G, p. (Met390Arg)/c.1135G>C, p.(Gly370Arg).
Resource table
Unique stem cell line identiﬁer KCi001-A
Alternative name(s) of stem cell line BBS1 Clone10
Institution Kennedy Center, Rigshospitalet
Contact information of distributor Lisbeth Birk Møller, Lisbeth.Birk.Moeller@regionh.dk
Type of cell line Induced pluripotent stem cell line (iPSC)
Origin Human
Additional origin info Female, Caucasian
Cell source Dermal ﬁbroblasts
Clonality Clonal
Method of reprogramming Nucleofection with non-integrating episomal plasmids carrying OCT3/4, SOX2, KLF4, L-MYC, LIN28 and
shP53
Genetic modiﬁcation NA
Type of modiﬁcation NA
Associated disease Autosomal recessive Bardet-Biedl syndrome
Gene/locus BBS1, Chr11: g.66293652 T > G, p.(Met390Arg); g.66293618G > C, p.(Gly379Arg); compound
heterozygous.
Ref sequence: NM_024649.4
Method of modiﬁcation NA
Name of transgene or resistance NA
Inducible/constitutive system NA
Date archived/stock date 25-01-2018
Cell line repository/bank NA
Ethical approval The study was approved by the regional scientiﬁc ethical committee in the Capital Region of Denmark
(H-3-2014-140). Written informed consent was obtained from the patients.
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1. Resource utility
Bardet-Biedl syndrome BBS is characterized by defective cilia
function. The BBS1 encoded protein is a member of the BBSome com-
plex, which is important for traﬃcking of membrane proteins in the
cilium. The generated iPSC line represents a useful source to investigate
the eﬀect of BBS1 in the pathophysiology of BBS.
2. Resource details
BBS is a rare, autosomal recessive disorder, where cellular, cilium-
dependent signalling is aﬀected. It has an estimated prevalence of 1/
59000 in Denmark (Hjortshøj et al., 2010). Primary cilia are micro-
tubule-based organelles, extending from the surface of most quiescent
vertebrate cells. The BBS1 protein is part of a protein complex termed
the BBSome and is thought to have a function in intra ﬂagellar transport
(IFT) in the primary cilium and in the connecting cilium, a specialized
primary cilium in photoreceptors. Previous studies have shown defec-
tive IFT as a result of pathogenic variants in the genes encoding the
proteins of the BBSome complex (Nager et al., 2017), but few studies
have focused on the function of BBS1 even though it is one of the most
frequently aﬀected protein in BBS (Forsythe and Beales, 2012).
Fibroblasts were obtained from a skin biopsy of a patient with
classic BBS symptoms, and compound heterozygous for the BBS1 var-
iants: c.1169T>G, p.(Met390Arg) and c.1135G>C, p. (Gly370Arg).
The ﬁbroblasts were reprogrammed into iPSC by nucleofection of three
non-integrating episomal plasmids, encoding the human genes; OCT3/
4, SOX2, KLF4, L-MYC, LIN28 and a p53 knock down shP53. Successful
isolation of the iPSC clone, KCi001-A was achieved and sequencing of
genomic DNA from KCi001-A conﬁrmed the retention of the BBS1
variants (Fig. 1A). Absence of integration of the episomal plasmids in
genomic DNA in KCi001-A, were veriﬁed by quantitative RT-PCR
analysis (Applied Biosystems 7500 Fast system) using plasmid speciﬁc
primers for OCT3/4, SOX-2, KLF4, LIN28 and L-MYC (Table 2), in the
presence of SYBR green (Fig. 1B). DNA from control ﬁbroblast 72 h post
transfection and DNA from un-transfected ﬁbroblasts were used as a
positive and negative control, respectively (Fig. 1B). Primers for the
corresponding endogenous genes were included as positive controls
(not shown). Normal karyotype of the generated iPSC was preserved
(46,XX) (Fig. 1C). Short tandem repeat (STR)-PCR proﬁle analysis,
where 22 diﬀerent loci were analysed, showed 100% identity match
between the parental ﬁbroblast cell line and KCi001-A (submitted in
archive with journal). Pluripotency was conﬁrmed by expression of the
genes, OCT4, NANOG, SOX-2, TDGF1, DNMT3B, GDF3and GARB3,
analysed by RT-qPCR using Taq-man probes (Fig. 1D). The mRNA level
of the diﬀerent genes, were normalized to GAPDH mRNA. RNA from
untreated ﬁbroblasts and from a control iPSC line was included as a
negative and a positive control, respectively (Fig. 1D). Pluripotency was
further supported by immunocytochemistry (ICC) demonstrating the
presence of the proteins Nanog and Oct4 in the nucleus, and the surface
epitopes recognized by SSEA3, Tra-1-60 and Tra-1-81 antibodies in the
cytoplasm (Fig. 1E). Furthermore, the capability of KCi001-A to dif-
ferentiate into cells of all three germ layers was carried out by spon-
taneous diﬀerentiation, initiated by embryoid body formation, followed
by adherent culture for a total of 21 days. The iPSC line showed positive
ICC staining for mesodermal (α-smooth muscle actin (SMA)), en-
dodermal (α-fetoprotein (AFP)) and ectodermal markers (βIII-tubulin
(βtub)) (Fig. 1F). All together these data show that we have successfully
created a BBS1 iPSC line; KCi001-A (Table 1).
3. Materials and methods
3.1. Reprogramming
Fibroblasts, were grown in DMEM-F12+GlutaMAX (Gibco), 10%
foetal bovine serum (FBS), 1% penicillin-streptomycin (Gibco) in a
37 °C humidiﬁed 5%-CO2 incubator. 5× 105 cells were transfected
with 1,25 ng of each of the three plasmids; hOct3/4, hSK, hUL
(Addgene plasmids #27077, #27078, #27080) in Primary Mammalian
Fibroblasts buﬀer (Lonza), using Amaxa Nucleofector™ 2b/program V-
Fig. 1. Characterization of BBS1 Clone 10 line (KCi001-A). A. WT sequences and mutations in KCi001-A in the same regions of the BBS1 gene. B. Quantitative real
time PCR showing absence of episomal plasmids in BBS1 Clone 10 (KCi001-A) and control ﬁbroblasts and presence of plasmids in transfected ﬁbroblasts. C.
Karyotype of representative metaphase showing normal 46 chromosomes (XX). D. mRNA expression of pluripotency markers in control iPSC line and in BBS1 Clone
10 (KCi001-A). E. Confocal images showing immunodetection of pluripotency-associated markers in BBS1 Clone 10 (KCi001-A). F. Immunoﬂuorescence analysis of in
vitro diﬀerentiation of BBS1 Clone 10 (KCi001-A) EBs using speciﬁc antibodies against the mesodermal marker α-smooth muscle actin (SMA), endodermal marker α-
fetoprotein (AFP) and the ectodermal marker βIII-tubulin (βtub). Nuclei were stained with DAPI. Scale bar 50µM.
Table 1
Characterization and validation.
Classiﬁcation Test Result Data
Morphology Photography Normal ES-like morphology Not shown
Phenotype Immunocytochemistry Positive for cell surface markers; Oct4, Nanog, SSEA3, Tra-1-60, Tra-1-81 Fig. 1 panel E
RT-qPCR (TaqMan probes; Applied
Biosystems 7500 Fast system)
Positive for; OCT4, NANOG, SOX2, TDGF1, DNMT3B, GARB3 and GDF3 Fig. 1 panel D
Genotype Karyotype (G-banding) and resolution 46,XX, resolution 450–500 Fig. 1 panel C
Identity Microsatellite PCR (mPCR) NA NA
STR analysis Elucigene QST*R PLUSv2 22 sites were tested. 100% identity match between parental ﬁbroblasts and
KCi001-A
submitted in archive with
journal
Variant analysis Sanger sequencing GENE: BBS1 Fig. 1 panel A
Compound heterozygous
Chr11: g.66293652 T > G, p.(Met390Arg)/g.66293618G > C, p.
(Gly379Arg)
Southern Blot OR WGS NA NA
Microbiology and
virology
Mycoplasma Mycoplasma testing by RT-PCR (negative) Supplementary File 1
Diﬀerentiation potential Embryoid body formation Presence of the proteins
α-smooth muscle actin (SMA), α-fetoprotein (AFP) and βIII-tubulin (βtub)
were used to conﬁrm formation of the three germ layers.
Fig. 1 panel F
Donor screening HIV 1+2 Hepatitis B, Hepatitis C NA NA
Genotype additional
info
Blood group genotyping NA NA
HLA tissue typing NA NA
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024 and seeded on gelatine coated dishes (Sigma) in ﬁbroblast medium
without antibiotics for 24 h followed by culturing in standard ﬁbroblast
medium. On day 6 after transfection, iPSCs were seeded on ESC grade
Matrigel (Corning) coated dishes, 50–80×103 cells/well, in mTeSR1
media (stem cell Technology) in an atmosphere of 5% CO2, 5% O2, 90%
N2 at 37 °C. From day 20 iPSC colonies were manually dissected. The
iPSCs were split using 0,5mM ultrapure EDTA (Gibco) at 70% con-
ﬂuency and frozen in mTeSR1 with 10% DMSO.
3.2. Karyotyping
Cells were treated with KaryoMAX colcemid for 45min, dissociated
and treated with hypotonic solution followed by ﬁxation in freshly
mixed 75% methanol: 25% acetic acid. Metaphase chromosomes were
stained with Giemsa for cytogenic analysis.
3.3. Genomic DNA isolation, integration, genotyping and short tandem
repeat (STR) analyses
DNA was puriﬁed using DNeasy Blood and Tissue kit (QIAGEN).
Integration analysis was performed by Quantitative PCR using plasmid
speciﬁc primers in the presence of SYBR green (Table 2). Data were
analysed using the ΔΔCT method and the amounts were normalized to
GAPDH. To conﬁrm the identity of the cell-line, genotyping was per-
formed with BBS1 speciﬁc primers and STR was performed using Elu-
cigene QST*R PLUSv2.
3.4. Quantitative real time reverse transcriptase polymerase chain reaction
(RT-qPCR)
RNA was harvested using RNeasy kit (QIAGEN), treated with DNase
I (Invitrogen,) and cDNA synthesized using high capacity cDNA kit
(Applied Biosystems). Taqman probes (Table 2) were used. Relative
standard curves were used for data analysed and amounts normalized
to GAPDH mRNA.
3.5. In vitro diﬀerentiation
The iPSC were treated with 0,5mM ultrapure EDTA (Gibco) and
plated in ultra-low adhesion plates (CORNING) in mTeSR1 media with
ROCK inhibitor, to induce formation of embryoid bodies. On day two
media was changed to DMEM-F12+GlutaMAX (Gibco), 20% knock-
out serum replacement (Gibco), 1× non-essential amino acids (Sigma),
0,1 mM 2-mecaptoethanol (Sigma) and 1% pen/strep After one week of
suspension culture the aggregates were transferred to adherent culture
in DMEM F-12 with GlutaMAX, 10% FBS and 1% pen/strep media on
Table 2
Reagents details.
Antibodies used for immunocytochemistry
Antibody Dilution Company Cat # and RRID
Pluripotency marker Rabbit anti-NANOG 1:500 PeproTech Cat# 500-P236, RRID: AB_1268805
Pluripotency marker Mouse anti-OCT3/4 1:200 Santa Cruz Biotechnology Cat# sc5279, RRID: AB_628051
Pluripotency marker Rat anti SSEA3 1:200 BioLegend Cat# 330302, RRID: AB_1236554
Pluripotency marker Mouse anti-TRA-1-60 1:200 BioLegend Cat# 330602, RRID: AB_1186144
Pluripotency marker Mouse anti-TRA-1-81 1:200 BioLegend Cat# 330702, RRID: AB_1089240
Diﬀerentiation marker, Mesoderm Mouse anti- α-smooth muscle actin (SMA) 1:500 Dako Cat# M0851, RRID: AB_2223500
Diﬀerentiation marker, Endoderm Rabbit anti-α-fetoprotein (AFP) 1:500 Dako Cat# A0008, RRID: AB_2650473
Diﬀerentiation marker, Ectoderm Mouse anti-βIII tubulin (βtub) 1:4000 Sigma-Aldrich Cat# T8660, RRID: AB_477590
Secondary antibody Alexa Flour Goat Anti-Rabbit 488 1:800 Life Technologies Cat# A11008, RRID: AB_143165
Secondary antibody Alexa Flour Donkey Anti-Mouse 546 1:800 Life Technologies Cat# A10036, RRID: AB_2534012
Secondary antibody Alexa Flour Rabbit Anti-Rat 488 1:800 Molecular Probes Cat# A-21210, RRID: AB_2535796
Primers
Target Forward/Reverse primer (5′-3′)
Episomal Plasmids (qPCR) OCT3/4 Plasmid CATTCAAACTGAGGTAAGGG/TAGCGTAAAAGGAGCAACATAG
Endogenous (qPCR) OCT3/4 Endogenous CCCCAGGGCCCCATTTTGGTACC/ACCTCAGTTTGAATGCATGGGAGAGC
Episomal Plasmids (qPCR) KLF4 Plasmid CCACCTCGCCTTACACATGAAGA/TAGCGTAAAAGGAGCAACATAG
Endogenous (qPCR) KLF4 Endogenous ACCCATCCTTCCTGCCCGATCAGA/TTGGTAATGGAGCGGCGGGACTTG
Episomal Plasmids (qPCR) SOX2 Plasmid TTCACATGTCCCAGCACTACCAGA/TTTGTTTGACAGGAGCGACAAT
Endogenous (qPCR) SOX2 Endogenous TTCACATGTCCCAGCACTACCAGA/TCACATGTGTGAGAGGGGCAGTGTGC
Episomal Plasmids (qPCR) L-MYC Plasmid GGCTGAGAAGAGGATGGCTAC/TTTGTTTGACAGGAGCGACAAT
Endogenous (qPCR) L-MYC Endogenous GCGAACCCAAGACCCAGGCCTGCTCC/CAGGGGGTCTGCTCGCACCGTGATG
Episomal Plasmids (qPCR) LIN28 Plasmid AGCCATATGGTAGCCTCATGTCCGC/TAGCGTAAAAGGAGCAACATAG
Endogenous (qPCR) LIN28 Endogenous AGCCATATGGTAGCCTCATGTCCGC/TCAATTCTGTGCCTCCGGGAGCAGGGTAGG
House-Keeping Gene (qPCR) GAPDH (1) ACCACAGTCCATGCCATCAC/TCCACCACCCTGTTGCTGTA
BBS1 patogenic variants (Seq.) BBS1 ex 12 GTGAGATTGGAGGGGAGATG/GGGATGCTGGGTGAACTAGA
Taqman probes
Target Assay ID
Pluripotency marker (RT-qPCR) POU5F1/OCT4 Thermo Fisher Scientiﬁc Hs04260367_g1
Pluripotency marker (RT-qPCR) NANOG Thermo Fisher Scientiﬁc Hs04260366_g1
Pluripotency marker (RT-qPCR) SOX2 Thermo Fisher Scientiﬁc Hs01053049_s1
Pluripotency marker (RT-qPCR) TDGF1 Thermo Fisher Scientiﬁc Hs02339497_g1
Pluripotency marker (RT-qPCR) DNMT3B Thermo Fisher Scientiﬁc Hs00171876_m1
Pluripotency marker (RT-qPCR) GARB3 Thermo Fisher Scientiﬁc Hs00241459_m1
Pluripotency marker (RT-qPCR) GDF3 Thermo Fisher Scientiﬁc Hs00220998_m1
House-Keeping Gene (RT-qPCR) GAPDH Thermo Fisher Scientiﬁc Hs99999905_m1
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gelatine (Sigma) coated coverslips. Morphological changes were ob-
served and after two weeks of adherent culture the cells were ﬁxed and
investigated by immunocytochemistry.
3.6. Immunocytochemistry
Cells grown on gelatine or matrigel (for pluripotency) coated cov-
erslips were ﬁxed with 4% paraformaldehyde (Hounisen) for 15min,
and permeabilized with 0,2% TritonX-100 in PBS for 15min. Slides
were incubated in blocking buﬀer for 1 h (3% BSA, 0,2% TritonX-100 in
PBS). Incubation with primary antibodies diluted in blocking buﬀer,
was performed for 2 h at RT or overnight at 5 °C followed by incubation
with secondary antibodies in blocking buﬀer (Table 2). Nuclei were
stained using DAPI.
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